Targeted Radiation Therapy and Molecular Imaging in Neuroendocrine Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 29 November 2024 | Viewed by 214
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neuroendocrine tumors (NETs) represent a group of highly heterogeneous neoplasms that can occur in different organs with an estimated incidence of less than 1/100,000 cases. They generally show an indolent growth rate. Gastroenteropancreatic (GEP) NETs constitute the second most common digestive cancer, demonstrating a low tendency to metastasize, but once they diffuse, they can rapidly progress. Pulmonary neuroendocrine tumors also demonstrate heterogeneity. NETs can be classified as grade 1 or 2 when well or moderately differentiated, respectively, or classified as grade 3 for poorly differentiated aggressive, neuroendocrine carcinoma (NEC). Moreover, the survival and outcome of NET patients with similar stages and grade differ considerably due to a plethora of prognostic factors, including the therapies implemented. Recently, the interest in the use of radioligand therapy (RTL) in the treatment of neuroendocrine tumors has grown, emerging as a therapeutic area in the field of both nuclear medicine and oncology. Diagnostic tools have also improved. RTL has been demonstrated to be well tolerated and economically sustainable, allowing for personalized medicine in the theragnostic era. Although well consolidated studies have already recognized the efficacy of this therapy, there is room to amplify its potentialities in terms of timing and the variety of neoplasms treated.
Dr. Giovanni Storto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NET
- GEP-NET
- NEC
- Ga-68 peptide PET/CT
- radioligand therapy
- NET theragnostic
- survival
- treatment timing
